Thelansis

Chronic Hand Eczema (CHE) Emerging Therapy and TPP Insights Thelansis’s “Chronic Hand Eczema (CHE) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Chronic Hand Eczema (CHE) Overview Chronic Hand Eczema is a persistent inflammatory skin disorder driven by epidermal barrier dysfunction, immune dysregulation involving Th2 and Th1 pathways, and repeated exposure to irritants or contact allergens. It presents with erythema, vesicles, fissuring, hyperkeratosis, and pruritus predominantly affecting the dorsal hands and fingers, with occupational exposure frequently implicated. Diagnosis is clinical, supported by patch testing to identify contact sensitization; IGA scoring and disease duration reflect severity. Topical corticosteroids and emoll...

Chronic Hand Eczema (CHE) Emerging Therapy and TPP Insights Thelansis’s “Chronic Hand Eczema (CHE) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product Profile...